Moreover, it has been reported that KV1.5 blockers used against AF can also inhibit TASK-1 (25), suggesting that a polypharmacological strategy targeting both KV1.5 and TASK-1 could enhance clinical efficacy. The gene discussed is KCNK3; the disease is atrial fibrillation.